Clinical Trials Search Results

  • Resize font
  • Print
  • Email
  • Facebook
  • Twitter
  • Google+
  • Pinterest
Display:
?
Drug:  nivolumab
Find trials that include:  Any drugs shown
Results 1-25 of 65 for your search:
Start Over
Nivolumab and Ipilimumab with or without Sargramostim in Treating Patients with Stage III-IV Melanoma That Cannot Be Removed by Surgery
Phase: Phase III, Phase II
Type: Biomarker/Laboratory analysis, Treatment
Age: 18 and over
Trial IDs: EA6141, NCI-2014-02674, NCT02339571
A Study of the Efficacy and Safety of Nivolumab Versus Bevacizumab and of Nivolumab With or Without Ipilimumab in Glioblastoma Patients at Different Stages of Treatment
Phase: Phase III
Type: Treatment
Age: 18 and over
Trial IDs: CA209-143, NCI-2014-00328, 2013-003738-34, NCT02017717
Dabrafenib and Trametinib Followed by Ipilimumab and Nivolumab or Ipilimumab and Nivolumab Followed by Dabrafenib and Trametinib in Treating Patients with Stage III-IV BRAFV600 Melanoma
Phase: Phase III
Type: Biomarker/Laboratory analysis, Treatment
Age: 18 and over
Trial IDs: EA6134, NCI-2014-01747, NCT02224781
Nivolumab Combined With Ipilimumab Versus Sunitinib in Previously Untreated Advanced or Metastatic Renal Cell Carcinoma (CheckMate 214)
Phase: Phase III
Type: Treatment
Age: 18 and over
Trial IDs: CA209-214, NCI-2014-01993, 2014-001750-42, NCT02231749
Efficacy Study of Nivolumab or Chemotherapy in Subjects With Relapsed Small-cell Lung Cancer
Phase: Phase III
Type: Treatment
Age: 18 and over
Trial IDs: CA209-331, NCI-2015-01362, 2015-001097-18, NCT02481830
Nivolumab after Surgery and Chemotherapy in Treating Patients with Stage IB-IIIA Non-small Cell Lung Cancer
Phase: Phase III
Type: Biomarker/Laboratory analysis, Treatment
Age: 18 and over
Trial IDs: EA5142, NCI-2015-01916, NCT02595944
A Study of Nivolumab Versus Sorafenib as First-Line Treatment in Patients With Advanced Hepatocellular Carcinoma
Phase: Phase III
Type: Treatment
Age: 18 and over
Trial IDs: CA209-459, NCI-2015-01952, NCT02576509
Study of Nivolumab Versus Temozolomide, Given With Radiation Therapy, for Newly-diagnosed Patients With Glioblastoma (GBM, a Malignant Brain Cancer)
Phase: Phase III
Type: Treatment
Age: 18 and over
Trial IDs: CA209-498, NCI-2016-00144, 2015-003739-37, NCT02617589
Study to Evaluate the Effectiveness, Safety and Tolerability of Nivolumab and the Combination Nivolumab Plus Ipilimumab in Subjects With Advanced Liver Cancer
Phase: Phase II, Phase I
Type: Biomarker/Laboratory analysis, Treatment
Age: 18 and over
Trial IDs: CA209-040, NCI-2013-00864, 2012-001514-42, NCT01658878
A Phase 1/2, Open-label Study of Nivolumab Monotherapy or Nivolumab Combined With Ipilimumab in Subjects With Advanced or Metastatic Solid Tumors
Phase: Phase II, Phase I
Type: Treatment
Age: 18 and over
Trial IDs: CA209-032, NCI-2013-02337, 2013-002844-10, NCT01928394
A Study of Nivolumab and Nivolumab Plus Ipilimumab in Recurrent and Metastatic Colon Cancer (CheckMate 142)
Phase: Phase II, Phase I
Type: Treatment
Age: 18 and over
Trial IDs: CA209-142, NCI-2014-00793, 2013-003939-30, NCT02060188
Study of the Safety and Tolerability of Urelumab Administered in Combination With Nivolumab in Solid Tumors and B-cell Non-Hodgkins Lymphoma
Phase: Phase II, Phase I
Type: Biomarker/Laboratory analysis, Treatment
Age: 18 and over
Trial IDs: CA186-107, NCI-2014-02119, 2014-002241-22, NCT02253992
RTA 408 Capsules in Patients With Melanoma - REVEAL
Phase: Phase II, Phase I
Type: Biomarker/Laboratory analysis, Treatment
Age: 18 and over
Trial IDs: RTA 408-C-1401, NCI-2015-00144, NCT02259231
Nivolumab with or without Ipilimumab in Treating Younger Patients with Recurrent or Refractory Solid Tumors or Sarcomas
Phase: Phase II, Phase I
Type: Biomarker/Laboratory analysis, Treatment
Age: 12 months to 30 years
Trial IDs: ADVL1412, NCI-2014-01222, NCT02304458
A Study of the Safety, Tolerability, and Efficacy of INCB24360 Administered in Combination With Nivolumab in Select Advanced Cancers
Phase: Phase II, Phase I
Type: Treatment
Age: 18 and over
Trial IDs: INCB 24360-204, NCI-2015-00040, NCT02327078
A Dose Escalation and Cohort Expansion Study of Anti-CD27 (Varlilumab) and Anti-PD-1 (Nivolumab) in Advanced Refractory Solid Tumors
Phase: Phase II, Phase I
Type: Treatment
Age: 18 and over
Trial IDs: CDX1127-02, NCI-2015-00273, NCT02335918
A Study of Galunisertib (LY2157299) in Combination With Nivolumab in Advanced Refractory Solid Tumors and in Recurrent or Refractory NSCLC, Hepatocellular Carcinoma, or Glioblastoma
Phase: Phase II, Phase I
Type: Biomarker/Laboratory analysis, Treatment
Age: 18 and over
Trial IDs: 15702, NCI-2015-02229, H9H-MC-JBEF, NCT02423343
Idarubicin, Cytarabine, and Nivolumab in Treating Patients with High-Risk Acute Myeloid Leukemia or Myelodysplastic Syndrome
Phase: Phase II, Phase I
Type: Treatment
Age: 18 and over
Trial IDs: 2014-0907, NCI-2015-01258, NCT02464657
Safety and Efficacy Study of Ulocuplumab and Nivolumab in Subjects With Solid Tumors
Phase: Phase II, Phase I
Type: Treatment
Age: 18 and over
Trial IDs: CA212-115, NCI-2015-01260, 2015-000136-15, NCT02472977
A Study to Investigate the Safety and Efficacy of Nivolumab in Virus-associated Tumors (CheckMate358)
Phase: Phase II, Phase I
Type: Treatment
Age: 18 and over
Trial IDs: CA209-358, NCI-2015-01356, 2015-000230-29, NCT02488759
A Study of BBI608 Administered in Combination With Immune Checkpoint Inhibitors in Adult Patients With Advanced Cancers
Phase: Phase II, Phase I
Type: Treatment
Age: 18 and over
Trial IDs: BBI608-201CIT, NCI-2015-01515, NCT02467361
A Study of Brentuximab Vedotin Combined With Nivolumab for Relapsed or Refractory Hodgkin Lymphoma
Phase: Phase II, Phase I
Type: Treatment
Age: 18 and over
Trial IDs: SGN35-025, NCI-2015-01867, NCT02572167
Start Over